Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 4/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | IL6 | P05231 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11072708 | 0.80 | NFKB1 (0.38) | ALDH1A1CTSSNFKB1MEN1KMT2A | |
| SCHEMBL6853771 | 0.79 | NFKB1 (0.44) | ALDH1A1TSHRCTSSPIM1PIM3 | |
| SCHEMBL29417728 | 0.79 | NFKB1 (0.57) | ALDH1A1TSHRPIM1PIM3NFKB1 | |
| SCHEMBL67207 | 0.79 | NFKB1 (0.57) | ALDH1A1TSHRPIM1PIM3NFKB1 | |
| SCHEMBL8230502 | 0.78 | NFKB1 (0.41) | CTSSNFKB1MEN1LMNAKMT2A | |
| SCHEMBL2451551 | 0.78 | ALDH1A1 (0.59) | ALDH1A1TSHRMEN1LMNATHRB | |
| SCHEMBL6630838 | 0.78 | TAS2R14 (0.46) | ALDH1A1CTSSTDP1TAS2R14NOTUM | |
| SCHEMBL622545 | 0.78 | ERN1 (0.44) | CTSSPIM1PIM3NFKB1MEN1 | |
| SCHEMBL1600817 | 0.78 | PIM1 (0.43) | PIM1PIM3NFKB1MEN1LMNA | |
| SCHEMBL6854167 | 0.78 | NFKB1 (0.47) | ALDH1A1PIM1PIM3NFKB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003200-A | P2X7 regulator | 詹森药业有限公司 | 2019-07-12 | — | — | CN | claimed |
| EP-3191492-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | claimed |
| CN-105209464-B | P2X7 modulators | 詹森药业有限公司 | 2019-01-01 | — | — | CN | claimed |
| EP-2970267-B3 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-30 | — | — | EP | claimed |
| CN-105209464-A | P2x7 modulators | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | claimed |
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4384165-B1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | disclosed |
| US-12338243-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-24 | — | — | US | disclosed |
| CN-101010323-A | Bicyclononene derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-01 | — | — | CN | disclosed |
| EP-1786814-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021402-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-4946566-A | PHOTOREDUCTION OF 9,10-PHENANTHRA-QUINONE AND DERIVATIVES | CANADIAN PATENTS & DEVELOPMENT LTD. (CA) | 1990-08-07 | — | — | US | disclosed |
| US-4224340-A | Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds | WILLIAM H. RORER, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4214003-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4197314-A | WITH A DIPHENYL NITRONE | WILLIAM H. RORER, INC. (US) | 1980-04-08 | — | — | US | disclosed |
| US-4153722-A | ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE | WILLIAM H. RORER, INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338243-B2 | P2X7 modulators | P2RX7, P2RX4, P2RX1 | ALDH1A1 1107/4885TSHR 2552/4885CTSS 2298/4885 |
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | ALDH1A1 3158/4885TSHR 3559/4885CTSS 1713/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | ALDH1A1 3260/4885TSHR 3357/4885CTSS 1863/4885 |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | ALDH1A1 266/4885TSHR 3000/4885CTSS 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.